HCA医疗 HCA 深 沪
等待开盘 08-25 09:30:00 美东时间
431.05
+1.860
+0.43%
华盛通- 最 高436.50
- 今 开432.90
- 成交量 58.22万股
- 最 低 429.69
- 昨 收 429.19
- 总市值 9332.30万
- 52周最高 554.96
- 市盈率 静 15.22
- 换手率 0.27%
- 52周最低 353.99
- 委 比 -57.69%
- 总股本 0.00亿
- 历史最高 554.96
- 量 比 0.69
- 振 幅 1.59%
- 历史最低 -2.04
- 每 手 1
- 风险率 48.12%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
JP Morgan Maintains Neutral on HCA Healthcare, Lowers Price Target to $425
JP Morgan analyst Benjamin Rossi maintains HCA Healthcare (NYSE:HCA) with a Neutral and lowers the price target from $490 to $425.
08-21 02:03
Wells Fargo Maintains Equal-Weight on HCA Healthcare, Raises Price Target to $381
Wells Fargo analyst Stephen Baxter maintains HCA Healthcare (NYSE:HCA) with a Equal-Weight and raises the price target from $369 to $381.
08-03 21:49
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
财报速睇 | HCA医疗 2026财年Q2营收202.30亿美元，同比增长8.7%；归母净利润16.99亿美元，同比增长2.8%
华盛资讯7月29日讯，HCA医疗公布2026财年Q2业绩，公司Q2营收202.30亿美元，同比增长8.7%，归母净利润16.99亿美元，同比增长2.8%。
07-29 05:41
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Behind HCA's Q2 Beat: One-Time Medicaid Boost and a Growing Insurance Headwind
Shares of HCA Healthcare Inc (NYSE:HCA) were rising on Monday, after the company reported its second-quarter results on Friday. Here are some key analyst takeaways: KeyBanc Capital Markets analyst Matthew Gillmor maintained an Overweight rating, while cutting the price target from $475 to $435. RBC ...
07-28 00:32
Oppenheimer Maintains Outperform on HCA Healthcare, Lowers Price Target to $485
Oppenheimer analyst Michael Wiederhorn maintains HCA Healthcare (NYSE:HCA) with a Outperform and lowers the price target from $520 to $485.
07-27 21:20
Barclays Maintains Equal-Weight on HCA Healthcare, Lowers Price Target to $387
Barclays analyst Andrew Mok maintains HCA Healthcare (NYSE:HCA) with a Equal-Weight and lowers the price target from $402 to $387.
07-27 19:43
HCA Healthcare Surpasses Q2 Estimates With Strong Admissions Growth
HCA Healthcare Inc. (NYSE:HCA), one of the largest hospital operators in the U.S., released second-quarter 2026 revenues of $20.23 billion, representing an 8.7% year-over-year increase, beating the consensus estimate of $19.40 billion. The company reported adjusted earnings of $7.59, up from $6.84 a...
07-24 23:33
